The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
The concept of neutral tumor evolution moves away from the classic Darwinian model of changing clonal dominance, and instead, in this model, clones with distinct mutational profiles can exist for longer periods of time. The tumor-driving mutations are thought to have arisen in the first malignant cell, with subsequent tumor evolution considered neutral and responsible for intra-tumor heterogeneity. In order to better understand the clonal evolution of Multiple Myeloma (MM), and the prognostic impact for patients, a study was carried out by David C. Johnson from the Division of Molecular Pathology at The Institute of Cancer Research, Sutton, UK, along with numerous collaborators, and published in Blood in August 2017.
Using 767 MM patients from two different treatment cohorts, almost a fifth of MM tumors were found have neutral evolutionary dynamics. This was also found to correlate with a lower PFS and OS in patients receiving iMiDs, and was attributed to reduced efficacy in these patients due to less influence on external factors. The use of such genetic analyses to further understand the evolutionary history of MM in a given patient could help to steer more tailored therapy, as well as providing further insight towards predicting patient outcome.
Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible influence on patient outcome we analysed whole exome sequencing tumor data for 333 patients from Myeloma XI, a UK phase III trial and 434 patients from the CoMMpass study, all of which had received immunomodulatory therapy (IMiD). By analysing mutant allele frequency distributions in tumors we found that 17-20% of MM is under neutral evolutionary dynamics. These tumors are associated with poorer patient survival in non-intensively treated patients, consistent with reduced therapeutic efficacy of micro-environment modulating IMiD drugs. Our findings provide evidence that knowledge of the evolutionary history of MM has relevance for predicting patient outcome and personalising therapy.
References